Genentech, a member of the Roche Group (RHHBY), Tuesday reported positive top line data from overall survival (OS) analysis of the Phase 3 INAVO120 study investigating Itovebi in combination with Ibrance and Fulvestrant for people with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, endocrine-resistant breast cancer.
Primary analysis showed the Itovebi-based regimen reached statistical significance, more than doubling progression-free survival in this patient population.
Previously, data from the primary analysis showed that Itovebi-based regimen reduced the risk of disease worsening or death by 57 percent compared with palbociclib and fulvestrant alone.
The U.S. Food and Drug Administration (FDA) approved the Itovebi-based regimen in October last year for the treatment of adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer.
The company noted that these OS results builds upon the previously reported primary analysis, which showed that the Itovebi-based regimen reduced the risk of disease worsening or death by 57% compared with palbociclib and fulvestrant alone
Itovebi is currently being investigated in four Phase 3 studies including INAVO120, INAVO121, INAVO122, and INAVO123 in PIK3CA-mutated locally advanced or metastatic breast cancer in various combinations.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.